Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-finding, Schedule-changing, Multi-center Study to Determine the Antibody Response to G17DT Treatment of Patients With Gastric Cancer.

NCT02233712 is registered in ClinicalTrials.gov with Cancer Advances Inc. as lead sponsor.

NCT NCT02233712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02233712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-finding, Schedule-changing, Multi-center Study to Determine the Antibody Response to G17DT Treatment of Patients With Gastric Cancer.
Lead sponsor
Cancer Advances Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 1999
Completion date
Not reported
Enrollment
33 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer